Several molecular-driven therapeutic programs are ongoing (for example, e-SMART, NCT02813135; INFORM2, NCT03838042; and the MATCH Screening Trial, NCT03155620), including with drugs of potential interest in osteosarcoma (e-SMART, NCT02813135, CDK4/6 inhibitor arms), and results are eagerly awaited. This evidence concerns the gene CDK4 and osteosarcoma.